Richard McCormick is a partner in the New York office of Mayer Brown's Intellectual Property practice. He has represented innovator pharmaceutical, biotech, and medical device companies in patent infringement and licensing dispute matters, including Hatch-Waxman litigations and inter partes reviews in the Patent Office. Richard has also advised clients on FDA regulatory issues implicating the patent laws, prepared patent validity/enforceability and freedom-to-operate opinions, and performed patent due diligence in connection with pre-litigation assessments, IP in-licensing and M&A transactions.

Before beginning his legal career, Richard was a Ph.D. candidate in biochemistry before becoming a research associate in the Department of Molecular Biology at Princeton University and the Department of Pediatric Oncology at the Dana-Farber Cancer Institute. Richard's knowledge base in the life sciences encompasses biochemistry, molecular and cellular biology, molecular genetics, protein chemistry, pharmacology, pharmaceutical formulation and controlled drug delivery, pharmaceutical solid state chemistry, small molecule drug discovery, RNA interference and antisense technology, and the production and characterization of recombinant therapeutic proteins (including antibodies).

Lenguajes Hablados

  • English


Representative Litigation and Trial Experience:

  • Amgen Inc. v. Sanofi, U.S. Sup. Ct. (2023), amicus brief filed by Unified Patents in support of Respondents

  • RiceTec Inc v. BASF SE, PGR2021-00113 and -0114 (as Lead Counsel)

  • Astellas US LLC v. Imperial College Innovations Limited, IPR2020-00764 (as Lead Counsel)

  • Chugai Pharmaceutical Co., Ltd v. Alexion Pharmaceuticals, Inc., D. Del (2018)

  • Certain Human Milk Oligosaccharides and Methods of Producing the Same, ITC (2018)

  • Genzyme v. Genentech and City of Hope, C.D. Cal. (2015) and related Inter Partes Reviews

  • Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals v. Genentech and City of Hope, C.D. Cal. (2015) and related Inter Partes Review (as Lead Counsel)

  • Washington Research Foundation v. Sanofi-Aventis U.S. LLC, W.D. Wash. (2015) and Fed. Cir. (2018)

  • Bristol‐Myers Squibb v. Genentech and City of Hope, C.D. Cal. (2013)

  • ViiV Healthcare v. Mylan Inc., D. Del. (2012)

  • Genentech Inc. v. Glaxo Group Ltd., GlaxoSmithKline and Human Genome Sciences, C.D. Cal. (2011)

  • Glaxo Group Ltd, GlaxoSmithKline and Lonza Biologics v. Genentech and City of Hope, C.D. Cal. (2010)

  • Biogen Idec, Inc. and Genentech v. GlaxoSmithKline et al., S.D. Cal. (2010)

  • Lectec Corp. v. Chattem Inc. et al., E.D. Tex. (2008)

  • LG Household & Health Care Ltd. et al. v. Warner Lambert Company LLC et al., D.N.J. (2007)

  • Lupin Limited v. Abbott Laboratories et al., E.D. Va. (2006)

  • Spectralytics, Inc. v. Cordis Corp., D. Minn. (2005)

  • Alza Corp. v. Impax Labs., Inc., N.D. Cal. (2003)

  • Alza Corp. v. Mylan Labs. and Mylan Pharms., N.D. W. Va. (2003) and Fed. Cir. (2005)

  • Alza Corp. and Janssen Pharmaceutica v. Mylan Labs. et al., D. Vt. (2002) and Fed. Cir. (2004)

  • Nextec Applications v. Marmot Mountain, Ltd, S.D. Cal. (2001)

  • Pfizer Inc. and Alza Corp. v. Andrx Corp., S.D. Fla. (2001)

  • Polytek Development Corp. v. Smooth-On, Inc., E.D. Pa. (1999)

  • Glaxo Wellcome, Inc. v. Genentech, Inc., D. Del. (1999) and Fed Cir. (2001)


Boston College Law School, JD

Fordham University, BS
Dean's List



  • Nueva York
  • Massachusetts